A brave NEO world: Neoadjuvant osimertinib in resectable EGFR-mutant NSCLC.

[1]  Shi Yan,et al.  Osimertinib as neoadjuvant therapy in patients with EGFR-mutant resectable stage II-IIIB lung adenocarcinoma (NEOS): A multicenter, single-arm, open-label phase 2b trial. , 2023, Lung cancer.

[2]  I. Wistuba,et al.  Predictive Biomarkers for Immunotherapy in Lung Cancer: Perspective from the IASLC Pathology Committee. , 2022, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[3]  N. Girard,et al.  Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer. , 2022, The New England journal of medicine.

[4]  Nofisat Ismaila,et al.  Management of Stage III Non–Small-Cell Lung Cancer: ASCO Guideline , 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  B. Corn,et al.  P47.10 Neoadjuvant Osimertinib in EGFR-Mutant Stage IIIA/B NSCLC - A Phase 2 Open-Label Pilot Study , 2021, Journal of Thoracic Oncology.

[6]  J. Riess,et al.  P26.02 A Phase II Trial of Neoadjuvant Osimertinib for Surgically Resectable EGFR-Mutant Non-Small Cell Lung Cancer: Updated Results , 2021, Journal of Thoracic Oncology.

[7]  S. Wang,et al.  P03.02 Osimertinib as Neoadjuvant Therapy for Resectable EGFR Mutant Non-small Cell Lung Cancer: A Real-World Multicenter Retrospective Study , 2021, Journal of Thoracic Oncology.

[8]  Caicun Zhou,et al.  Differences in Immunological Landscape between EGFR-Mutated and Wild-Type Lung Adenocarcinoma , 2021, Disease markers.

[9]  J. Roth,et al.  Oncogene-specific differences in tumor mutational burden, PD-L1 expression, and outcomes from immunotherapy in non-small cell lung cancer , 2021, Journal for ImmunoTherapy of Cancer.

[10]  L. Zhong,et al.  Small molecules in targeted cancer therapy: advances, challenges, and future perspectives , 2021, Signal Transduction and Targeted Therapy.

[11]  Ash A. Alizadeh,et al.  Noninvasive Early Identification of Therapeutic Benefit from Immune Checkpoint Inhibition , 2020, Cell.

[12]  I. Wistuba,et al.  Neoadjuvant chemotherapy and nivolumab in resectable non-small-cell lung cancer (NADIM): an open-label, multicentre, single-arm, phase 2 trial. , 2020, The Lancet. Oncology.

[13]  M. Tsuboi,et al.  Osimertinib in Resected EGFR-Mutated Non-Small-Cell Lung Cancer. , 2020, The New England journal of medicine.

[14]  Haiquan Chen,et al.  Gefitinib as neoadjuvant therapy for resectable stage II-IIIA non-small cell lung cancer: A phase II study. , 2020, The Journal of thoracic and cardiovascular surgery.

[15]  Ying Cheng,et al.  Erlotinib Versus Gemcitabine Plus Cisplatin as Neoadjuvant Treatment of Stage IIIA-N2 EGFR-Mutant Non-Small-Cell Lung Cancer (EMERGING-CTONG 1103): A Randomized Phase II Study. , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  B. Han,et al.  Erlotinib as Neoadjuvant Therapy in Stage IIIA (N2) EGFR Mutation‐Positive Non‐Small Cell Lung Cancer: A Prospective, Single‐Arm, Phase II Study , 2018, The oncologist.

[17]  Ying Cheng,et al.  Osimertinib in Untreated EGFR‐Mutated Advanced Non–Small‐Cell Lung Cancer , 2018, The New England journal of medicine.

[18]  M Oudkerk,et al.  Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

[19]  J. Cooper.  Ajcc Cancer Staging Manual , 1997 .